#biotech #Netherlands #GenScript #Delft #mRNA

GenScript Expands mRNA Production Footprint in Europe

In a significant move to bolster its global biotechnology network, GenScript officially inaugurated its first European mRNA production site in Delft, Netherlands, on March 12, 2026. This development reinforces Europe as a vital element of GenScript's integrated research and development (R&D) and production infrastructure. As demand for next-generation therapies and advanced biologics accelerates, the Delft facility positions GenScript to offer better support to European innovators.

The strategic establishment of the mRNA production site not only enhances regional accessibility but also aligns with EU regulatory standards, ensuring that collaborations between stakeholders are streamlined and effective. "Having a local GenScript facility in the EU makes a real difference for us," commented Dr. Paula Río from CIEMAT/CIBERER/FJD, UAM. The proximity of operations allows for seamless communication, reduced shipping delays, and enhanced cooperation, thereby accelerating development timelines for projects in hematology and other fields.

Shawn Wu, President of GenScript's EU Division, emphasized that Europe is not just an adjunct to their operations but a foundational pillar of their global mRNA platform. "By integrating Delft into our unified global system, we can better serve our partners through improved speed and operational resilience while adhering to consistent global standards,” he noted.

Core Capabilities of the Delft Facility

One of the standout features of the Delft site is its comprehensive end-to-end capabilities for mRNA workflows. These include:

• - Gene design and synthesis
• - Vector engineering
• - In vitro transcription (IVT) mRNA production
• - Proprietary GenCap™ mRNA capping technology
• - UTR optimization and formulation support

This facility benefits from GenScript's AI-driven digital operating model, ensuring consistent processes and swift turnaround times. The integration of local operations with global quality systems allows customers to transition efficiently from research-grade mRNA to advanced development stages.

The opening of the Delft facility follows recent expansions at GenScript’s U.S. campus in New Jersey, signaling a concerted effort to enhance their global presence in biotechnology. With operations now established across North America, Europe, and Asia, GenScript is committed to creating robust platforms that promote life science innovation, supporting everything from early research to more advanced stages of development.

Commitment to European Biotech Ecosystem

GenScript’s engagement in Europe deepened when it established its European Division headquarters in the Netherlands in 2021. The new site in Delft underscores its long-term vision for sustainability and innovation in the region. Cindy Gerhardt, Managing Director of Planet B.io, praised GenScript’s commitment to scientific excellence and collaboration, stating that their partnership aims to accelerate the pace of biotech research. The new lab enhances the Biotech Campus Delft, fostering a synergistic atmosphere for the regional ecosystem.

Sherry Shao, CEO of GenScript Biotech Corporation, spoke about the company's ongoing commitment to delivering high-quality biotechnology solutions that empower scientific discovery. She pointed out that this expansion is part of GenScript's broader strategy to foster innovation worldwide. As the company advances its mRNA capabilities, it aims to offer integrated systems that allow for effective transitions from conceptualization to realization of innovative treatments.

Looking Ahead: The Future of mRNA Innovation

The establishment of the Delft facility marks a pivotal step in GenScript's commitment to adapt and thrive in the fast-evolving biotech landscape. The company is building scalable and automated platforms designed to meet the needs of tomorrow’s therapeutic developments.

Since its inception in 2002, GenScript has positioned itself as a cornerstone of the global life science industry. Collaborating with academic institutions and industry leaders, the company has established itself as a leader in providing the essential building blocks necessary for groundbreaking healthcare solutions. Guided by its mission of enhancing human and environmental health through biotechnology, GenScript now supports over 200,000 customers in more than 100 countries.

Conclusion

As GenScript embarks on this new chapter with the opening of its European mRNA production hub, it continues to redefine the standards of excellence in the biotech space. With a strong commitment to innovation and quality, GenScript is poised to play a significant role in the future of biotechnology, contributing to advancements that improve health outcomes globally.